<H1>Chapter DOI: 10.1007/978-1-60327-829-4_29<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>60</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>58</td></tr><tr><td>BibStructured Count</td><td width="10%">59</td></tr><tr><td>BibUnstructured Count</td><td width="10%">1</td></tr><tr><td>DOI already available in SpringerLink</td><td>42</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>6</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>6</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>6</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>4</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_29</td><td>BibArticle</td><td>Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005;55(1):10&#8211;30.</td><td><a href=http://dx.doi.org/10.3322/canjclin.55.1.10>10.3322/canjclin.55.1.10</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_29</td><td>BibUnstructured</td><td><span style='background:#FFD9B3'>SEER Cancer Statistics Review</span>. <span style='background:#FFFF49'>National Cancer Institute</span>. <span style='background:#C0FFC0'>Bethesda, MD</span>; 1975&#8211;2005. <span style='background:#FF3300'>http://www.seer.cancer.gov/csr/1975_2005/</span>. Accessed 13 Feb <span style='background:#66FF66'>2009</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3_29</td><td>BibArticle</td><td>Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 1990;144(5):1180&#8211;4.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4_29</td><td>BibArticle</td><td>Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000;163(4):1155&#8211;60.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)67713-0>10.1016/S0022-5347(05)67713-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_29</td><td>BibArticle</td><td>Dillioglugil O, Leibman BD, Kattan MW, Seale-Hawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 1997;50(1):93&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(97)00106-4>10.1016/S0090-4295(97)00106-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_29</td><td>BibArticle</td><td>Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591&#8211;7.</td><td><a href=http://dx.doi.org/10.1001/jama.281.17.1591>10.1001/jama.281.17.1591</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_29</td><td>BibArticle</td><td>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502&#8211;12.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa040720>10.1056/NEJMoa040720</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_29</td><td>BibArticle</td><td>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513&#8211;20.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa041318>10.1056/NEJMoa041318</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_29</td><td>BibArticle</td><td>Lombard M, Pastoret PP, Moulin AM. A brief history of vaccines and vaccination. Rev Sci Tech 2007;26(1):29&#8211;48.</td><td><a href=http://dx.doi.org/10.20506/rst.26.1.1724>10.20506/rst.26.1.1724</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, ArticleTitle, Author_FamilyName_1, Year, FirstPage, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR10_29</td><td>BibArticle</td><td>Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957;18(6):769&#8211;78.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11_29</td><td>BibArticle</td><td>Brannen GE, Gomolka DM, Coffey DS. Specificity of cell membrane antigens in prostatic cancer. Cancer Chemother Rep 1975;59(1):127&#8211;38.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12_29</td><td>BibArticle</td><td>Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995;46(5):681&#8211;6. Discussion 686&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(99)80301-X>10.1016/S0090-4295(99)80301-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_29</td><td>BibArticle</td><td>Sanda MG, Restifo NP, Walsh JC, et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995;87(4):280&#8211;5.</td><td><a href=http://dx.doi.org/10.1093/jnci/87.4.280>10.1093/jnci/87.4.280</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_29</td><td>BibArticle</td><td>Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90(8):3539&#8211;43.</td><td><a href=http://dx.doi.org/10.1073/pnas.90.8.3539>10.1073/pnas.90.8.3539</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_29</td><td>BibArticle</td><td>Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 2000;7(3):168&#8211;73.</td><td><a href=http://dx.doi.org/10.1097/00062752-200005000-00007>10.1097/00062752-200005000-00007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_29</td><td>BibArticle</td><td>Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392(6673):245&#8211;52.</td><td><a href=http://dx.doi.org/10.1038/32588>10.1038/32588</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_29</td><td>BibArticle</td><td>Vieweg J, Rosenthal FM, Bannerji R, et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994;54:1760&#8211;5.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18_29</td><td>BibArticle</td><td>Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994;151(3):622&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_29</td><td>BibArticle</td><td>Moody DB, Robinson JC, Ewing CM, Lazenby AJ, Isaacs WB. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate 1994;24(5):244&#8211;51.</td><td><a href=http://dx.doi.org/10.1002/pros.2990240505>10.1002/pros.2990240505</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_29</td><td>BibArticle</td><td>Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57(8):1537&#8211;46.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)63906-5>10.1016/S0022-5347(01)63906-5</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR21_29</td><td>BibArticle</td><td>Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59(20):5160&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22_29</td><td>BibArticle</td><td>Emens LA, Reilly RT, Jaffee EM. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer 2005;12(1):1&#8211;17.</td><td><a href=http://dx.doi.org/10.1677/erc.1.00671>10.1677/erc.1.00671</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_29</td><td>BibArticle</td><td>Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 2006;24(5):419&#8211;24.</td><td><a href=http://dx.doi.org/10.1016/j.urolonc.2005.08.021>10.1016/j.urolonc.2005.08.021</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_29</td><td>BibArticle</td><td>Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer &#8211; science driving clinical progress. Nat Rev 2005;5(6):459&#8211;67.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1038/nrc1630>10.1038/nrc1630</a></td><td><b>CrossRef-Meta</b></td>
<td>IssueID, VolumeID, Author_FamilyName_1, Year, Author_FamilyName_2, FirstPage</td><td>CrossRef</td></tr><tr><td>CR25_29</td><td>BibArticle</td><td>Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004;96(4):326&#8211;31.</td><td><a href=http://dx.doi.org/10.1093/jnci/djh028>10.1093/jnci/djh028</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_29</td><td>BibArticle</td><td>Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 2006;12(11 Pt 1):3394&#8211;401.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-06-0145>10.1158/1078-0432.CCR-06-0145</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_29</td><td>BibArticle</td><td>Simons JW, Nelson WG, Nemunaitis J, et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2002;21:729.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28_29</td><td>BibArticle</td><td>Groh V, Li YQ, Cioca D, et al. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A 2005;102(18):6461&#8211;6.</td><td><a href=http://dx.doi.org/10.1073/pnas.0501953102>10.1073/pnas.0501953102</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_29</td><td>BibArticle</td><td>Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9(2):606&#8211;12.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR30_29</td><td>BibArticle</td><td>Walunas TL, Bluestone JA. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol 1998;160(8):3855&#8211;60.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR31_29</td><td>BibArticle</td><td>Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005;25(21):9543&#8211;53.</td><td><a href=http://dx.doi.org/10.1128/MCB.25.21.9543-9553.2005>10.1128/MCB.25.21.9543-9553.2005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_29</td><td>BibArticle</td><td>Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60(9):2444&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR33_29</td><td>BibArticle</td><td>Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 1999;96(26):15074&#8211;9.</td><td><a href=http://dx.doi.org/10.1073/pnas.96.26.15074>10.1073/pnas.96.26.15074</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_29</td><td>BibArticle</td><td>Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997;94(15):8099&#8211;103.</td><td><a href=http://dx.doi.org/10.1073/pnas.94.15.8099>10.1073/pnas.94.15.8099</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_29</td><td>BibArticle</td><td>Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027&#8211;34.</td><td><a href=http://dx.doi.org/10.1084/jem.192.7.1027>10.1084/jem.192.7.1027</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_29</td><td>BibArticle</td><td>Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99(19):12293&#8211;7.</td><td><a href=http://dx.doi.org/10.1073/pnas.192461099>10.1073/pnas.192461099</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_29</td><td>BibArticle</td><td>Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793&#8211;800.</td><td><a href=http://dx.doi.org/10.1038/nm0902-1039c>10.1038/nm0902-1039c</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, ArticleTitle, Author_FamilyName_1, Year, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR38_29</td><td>BibArticle</td><td>Sun J, Xu K, Wu C, et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens 2007;69(1):19&#8211;27.</td><td><a href=http://dx.doi.org/10.1111/j.1399-0039.2006.00701.x>10.1111/j.1399-0039.2006.00701.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_29</td><td>BibArticle</td><td>Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004;64(3):1140&#8211;5.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-03-3259>10.1158/0008-5472.CAN-03-3259</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_29</td><td>BibArticle</td><td>Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007;109(8):1499&#8211;505.</td><td><a href=http://dx.doi.org/10.1002/cncr.22588>10.1002/cncr.22588</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_29</td><td>BibArticle</td><td>Roth TJ, Sheinin Y, Lohse CM, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007;67(16):7893&#8211;900.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-07-1068>10.1158/0008-5472.CAN-07-1068</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42_29</td><td>BibArticle</td><td>Martin-Orozco N, Wang YH, Yagita H, Dong C. Cutting edge: programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. J Immunol 2006;177(12):8291&#8211;5.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.4049/jimmunol.177.12.8291>10.4049/jimmunol.177.12.8291</a></td><td><b>CrossRef-Meta</b></td>
<td>IssueID, VolumeID, Author_FamilyName_1, Year, Author_FamilyName_2, FirstPage</td><td>CrossRef</td></tr><tr><td>CR43_29</td><td>BibArticle</td><td>Wang L, Fraser CC, Kikly K, et al. B7-H3 promotes acute and chronic allograft rejection. Eur J Immunol 2005;35(2):428&#8211;38.</td><td><a href=http://dx.doi.org/10.1002/eji.200425518>10.1002/eji.200425518</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_29</td><td>BibArticle</td><td>Xu J, Huang B, Xiong P, et al. Soluble mouse B7-H3 down-regulates dendritic cell stimulatory capacity to allogenic T cell proliferation and production of IL-2 and IFN-gamma. Cell Mol Immunol 2006;3(3):235&#8211;40.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR45_29</td><td>BibArticle</td><td>Nurieva R, Thomas S, Nguyen T, et al. T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J 2006;25(11):2623&#8211;33.</td><td><a href=http://dx.doi.org/10.1038/sj.emboj.7601146>10.1038/sj.emboj.7601146</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46_29</td><td>BibArticle</td><td>Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity 2004;21(4):503&#8211;13.</td><td><a href=http://dx.doi.org/10.1016/j.immuni.2004.08.010>10.1016/j.immuni.2004.08.010</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_29</td><td>BibArticle</td><td>Zhu X, Yang P, Zhou H, et al. CD4+ CD25+ Tregs express an increased LAG-3 and CTLA-4 in anterior chamber-associated immune deviation. Graefe&#8217;s Arch Clin Exp Ophthalmol 2007;245(10):1549&#8211;57.</td><td><a href=http://dx.doi.org/10.1007/s00417-007-0591-8>10.1007/s00417-007-0591-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48_29</td><td>BibArticle</td><td>Zarek PE, Huang CT, Lutz ER, et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 2008;111(1):251&#8211;9.</td><td><a href=http://dx.doi.org/10.1182/blood-2007-03-081646>10.1182/blood-2007-03-081646</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49_29</td><td>BibArticle</td><td>Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007;117(11):3383&#8211;92.</td><td><a href=http://dx.doi.org/10.1172/JCI31184>10.1172/JCI31184</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50_29</td><td>BibArticle</td><td>Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281(5380):1191&#8211;3.</td><td><a href=http://dx.doi.org/10.1126/science.281.5380.1191>10.1126/science.281.5380.1191</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51_29</td><td>BibArticle</td><td>Kudo Y, Boyd CA, Spyropoulou I, et al. Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta. J Reprod Immunol 2004;61(2):87&#8211;98.</td><td><a href=http://dx.doi.org/10.1016/j.jri.2003.11.004>10.1016/j.jri.2003.11.004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52_29</td><td>BibArticle</td><td>Mellor AL, Sivakumar J, Chandler P, et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001;2(1):64&#8211;8.</td><td><a href=http://dx.doi.org/10.1038/83183>10.1038/83183</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53_29</td><td>BibArticle</td><td>Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189(9):1363&#8211;72.</td><td><a href=http://dx.doi.org/10.1084/jem.189.9.1363>10.1084/jem.189.9.1363</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54_29</td><td>BibArticle</td><td>Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9(10):1269&#8211;74.</td><td><a href=http://dx.doi.org/10.1038/nm934>10.1038/nm934</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR55_29</td><td>BibArticle</td><td>Friberg M, Jennings R, Alsarraj M, et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 2002;101(2):151&#8211;5.</td><td><a href=http://dx.doi.org/10.1002/ijc.10645>10.1002/ijc.10645</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR56_29</td><td>BibArticle</td><td>Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11(3):312&#8211;9.</td><td><a href=http://dx.doi.org/10.1038/nm1196>10.1038/nm1196</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57_29</td><td>BibArticle</td><td>Ou X, Cai S, Liu P, et al. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J Cancer Res Clin Oncol 2008;134(5):525&#8211;33.</td><td><a href=http://dx.doi.org/10.1007/s00432-007-0315-9>10.1007/s00432-007-0315-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58_29</td><td>BibArticle</td><td>Nigam A, Yacavone RF, Zahurak ML, et al. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol 1998;12(1):161&#8211;70.</td><td><a href=http://dx.doi.org/10.3892/ijo.12.1.161>10.3892/ijo.12.1.161</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, JournalTitle, Author_FamilyName_2, Year</td><td>CrossRef</td></tr><tr><td>CR59_29</td><td>BibArticle</td><td>Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005;65(18):8059&#8211;64.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-05-1797>10.1158/0008-5472.CAN-05-1797</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60_29</td><td>BibArticle</td><td>Harris TJ, Hipkiss EL, Borzillary S, et al. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 2008;68(12):1319&#8211;29.</td><td><a href=http://dx.doi.org/10.1002/pros.20794>10.1002/pros.20794</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>